

## Phospho-Cbl (Y700) Polyclonal Antibody

### Description

<b>Product type</b>	Primary Antibody
<b>Code</b>	BT-PHS00876
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Size</b>	20ul, 50ul, 100ul
<b>Immunogen</b>	The antiserum was produced against synthesized peptide derived from human CBL around the phosphorylation site of Tyr700. AA range:666-715
<b>Mol wt</b>	99647
<b>Species reactivity</b>	Human, mouse, rat
<b>Clonality</b>	Polyclonal
<b>Recommended application</b>	WB, IHC-p, IF, ELISA
<b>Concentration</b>	1 mg/ml
<b>Full name</b>	Phospho-Cbl (Y700) Antibody
<b>Synonyms</b>	CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL

**This product is for research use only, not for use in human, therapeutic or diagnostic procedure.**

### Background

CBL (Cbl proto-oncogene) is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. CBL has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in CBL are also the cause of Noonan syndrome-like disorder.

### Recommended Dilution

WB: 1: 500 - 1: 2000

IHC: 1: 100 - 1: 300

IF: 1: 200 - 1: 1000

ELISA: 1: 10000

Not yet tested in other applications.

### Images

No images.

### Storage

-20°C for one year